Skip to content

Corcept Therapeutics CORT Lease Liability Payments - Remainder of Fiscal Year

Lease Liability Payments - Remainder of Fiscal Year at other companies

BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$9.12M
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Natera, Inc. logo
Natera, Inc.NTRA

Other financials

Income statement

See full
Revenue$164.9M+4.9%
Gross profit$162.0M+4.7%
Operating income-$49.6M-1,552%
Net income-$31.8M-255%
EPS (diluted)-$0.30-276%

Balance sheet

See full
Cash & equivalents$110.0M+21.1%
Total debt$9.6M+41.0%
Total equity$638.0M-6.6%
Total assets$814.9M-3.7%

Cash flow

See full
Operating cash flow-$16.8M-452%
CapEx$201.0K+93.3%
Free cash flow-$17.0M-464%

Valuation

See full
Market cap$8.58B-64.4%
Enterprise value$8.48B-65.0%
P/E181.2×+1.3×
P/S11.2×-24.0×

Profitability

See full
Gross margin98.3%-0.2pp
Operating margin-1.1%-17.2pp
Net margin6.2%-13.4pp
FCF margin15.6%-10.2pp

Returns & leverage

See full
Return on equity7.2%-14.6pp
Debt / equity0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's lease liability payments - remainder of fiscal year.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corcept Therapeutics's lease liability payments - remainder of fiscal year?
Corcept Therapeutics (CORT) reported lease liability payments - remainder of fiscal year of $2.7M in Q1 2026.
How has Corcept Therapeutics's lease liability payments - remainder of fiscal year changed year-over-year?
Corcept Therapeutics's lease liability payments - remainder of fiscal year increased by 73.9% year-over-year, from $1.55M to $2.7M.
What does lease liability payments - remainder of fiscal year mean?
The contractual cash obligations for operating and finance leases due within the remaining months of the current fiscal year. This provides a short-term view of the company's fixed lease commitments. It is a critical component for assessing near-term liquidity and cash flow requirements.